Redwood Bioscience is utilizing precision protein-chemical engineering for drug conjugate optimization. Hybrid therapeutics are emerging as an important class of drugs. These products combine the binding specificity and half-life benefits of biologic “carriers”, with the potency advantages of small molecule and synthetic peptide ”cargo”. Redwood’s site specific protein modification technology overcomes the challenges associated with conjugating biologics to synthetic molecules. The Company’s approach provides control and flexibility over cargo location and loading on a carrier, producing homogenous therapeutics. The chemical orientation of a payload can be optimized to enhance drug-target interactions for improved conjugate potency. Control over cargo placement, number and orientation enables generation of chemically modified protein libraries for optimal conjugate selection.
Leveraging site specifically modified protein scaffolds, Redwood is developing antibody-drug conjugates with enhanced efficacy and safety and peptide therapeutics with improved half- lives and potency.